FrancophonIA/ELRC3.0 huggingface dataset:
English: NAME OF THE MEDICINAL PRODUCT Valtrex and associated names (see Annex I) 500 mg film-coated tablets [See Annex I - To be completed nationally] Valaciclovir STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains valaciclovir hydrochloride equivalent to 500 mg valaciclovir LIST OF EXCIPIENTS
Estonian: RAVIMPREPARAADI NIMETUS Valtrex ja sarnased nimetused (vaata Lisa 1) 500 mg õhukese polümeerikattega tabletid [Vaata Lisa I - täidetakse riiklikult] Valaciclovirum TOIMEAINE(TE) SISALDUS Üks tablett sisaldab valatsikloviirvesinikkloriidi, mis vastab 500 mg valatsikloviirile.
English: please tell your doctor or pharmacist.
Estonian: Enne ravimi kasutamist pidage nõu oma arsti või apteekriga.
English: • tremors
Estonian: • värinad
English: • low back pain (kidney pain)
Estonian: • alaseljavalu (neeru valu)
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.
Estonian: Farmakoloogilise ohutuse, kroonilise toksilisuse, genotoksilisuse, kartsinogeensuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Studies of valaciclovir treatment and suppression for genital herpes were performed in HIV/HSV coinfected patients.
Estonian: Valatsikloviir-ravi ja genitaalherpese pärssimise uuringuid on viidud läbi patsientidel, kes põevad nii HIV kui HSV nakkust üheaegselt, kelle keskmine CD4 arv > 100 rakku/mm3.
English: The CHMP endorsed also contraindications regarding hypersensitivity to ACV, VACV or formulations of VACV.
Estonian: Inimravimite komitee kiitis vastunäidustusena heaks ülitundlikkuse atsikloviiri, valatsikloviiri või valatsikloviiri erinevate ravimvormide suhtes.
English: White, biconvex, elongated tablet with a white to off-white core, engraved “GX CF1” on one side.
Estonian: 500 mg tablett Valge, kaksikkumer, piklik tablett, valge kuni valkja sisuga, ühel pool markeering “GX CF1”
English: Use in CMV infections
Estonian: Kasutamine tsütomegaloviiruse infektsiooni ravis
English: • feeling agitated
Estonian: • erutuvus
English: Oral valaciclovir 1000 mg TID for 7-10 days is a recommended treatment option for acute localized dermatomal herpes zoster in HIV-infected patients.
Estonian: Soovitatav annustamisskeem ägeda lokaliseerunud dermatoomse vöötohatise korral HIV-infektsiooniga patsientidel on 1000 mg valatsikloviiri suukaudselt kolm korda ööpäevas 7…10 päeva vältel.
English: NAME OF THE MEDICINAL PRODUCT Valtrex and associated names (see Annex I) 1000 mg film-coated tablets [See Annex I - To be completed nationally] Valaciclovir
Estonian: RAVIMPREPARAADI NIMETUS Valtrex ja sarnased nimetused (vaata Lisa 1) 1000 mg õhukese polümeerikattega tabletid [Vaata Lisa I - täidetakse riiklikult] Valaciclovirum MÜÜGILOA HOIDJA NIMI [Vaata Lisa I - täidetakse riiklikult] KÕLBLIKKUSAEG
English: Other uncommon side effects:
Estonian: Teised aeg-ajalt esinevad kõrvaltoimed:
English: • shortness of breath (dyspnoea)
Estonian: • hingeldus (düspnoe)
English: Talk to your doctor or pharmacist if you take too much Valtrex.
Estonian: Kui te võtate liiga palju Valtrex'it, rääkige oma arsti või apteekriga.
English: NAME OF THE MEDICINAL PRODUCT Valtrex and associated names (see Annex I) 500 mg film-coated tablets [See Annex I - To be completed nationally] Valaciclovir NAME OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] EXPIRY DATE EXP {MM YYYY} BATCH NUMBER
Estonian: RAVIMPREPARAADI NIMETUS Valtrex ja sarnased nimetused (vaata Lisa 1) 500 mg õhukese polümeerikattega tabletid [Vaata Lisa I - täidetakse riiklikult] Valaciclovirum MÜÜGILOA HOIDJA NIMI [Vaata Lisa I - täidetakse riiklikult] KÕLBLIKKUSAEG
English: NAME OF THE MEDICINAL PRODUCT Valtrex and associated names (see Annex I) 250 mg film-coated tablets [See Annex I - To be completed nationally] Valaciclovir NAME OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] EXPIRY DATE EXP {MM YYYY} BATCH NUMBER
Estonian: RAVIMPREPARAADI NIMETUS Valtrex ja sarnased nimetused (vaata Lisa 1) 250 mg õhukese polümeerikattega tabletid [Vaata Lisa I - täidetakse riiklikult] Valaciclovirum MÜÜGILOA HOIDJA NIMI [Vaata Lisa I - täidetakse riiklikult] KÕLBLIKKUSAEG
English: The CHMP agreed a reduced dosage in renal impairment.
Estonian: Inimravimite komitee kinnitas väiksemad annused neerupuudulikkusega patsientidele.
English: GlaxoSmithKline UK
Estonian: GlaxoSmithKline s.a.
English: • stomach discomfort
Estonian: • ebamugavustunne maos
English: Valaciclovir is a prodrug of aciclovir.
Estonian: Valatsikloviir on atsikloviiri eelravim.
English: • feeling very drowsy
Estonian: • äärmuslik uimasus
English: Bottle (glass)
Estonian: Pudel (klaasist)
English: 20 mg/ml Oral solution
Estonian: 20 mg/ml Suukaudne lahus
English: 300 ml (20 mg/ml)
Estonian: 300 ml (20 mg/ml) 1 pudel + 1 mõõtekork + 1 suusüstal
English: Invented name Strength Pharmaceutical Form Route of Administration
Estonian: Ravimi väljamõeldud nimetus
English: The European Commission granted a marketing authorisation valid throughout the European Union for Abilify on 4 June 2004.
Estonian: Euroopa Komisjon andis Abilify müügiloa, mis kehtib kogu Euroopa Liidus, 4. juunil 2004.
English: What measures are being taken to ensure the safe and effective use of Abilify?
Estonian: Mis meetmed võetakse, et tagada Abilify ohutu ja efektiivne kasutamine?
English: The full EPAR for Abilify can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Abilify kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: With regard to safety, the medicine has side effects comparable to those of other antipsychotics.
Estonian: Ohutusega seoses on ravimi kõrvalnähud võrreldavad muude antipsühhootikumide omadega.
English: Other information about Abilify
Estonian: Muu teave Abilify kohta
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that the benefits of Abilify are greater than its risks and recommended its approval in the EU.
Estonian: Inimravimite komitee otsustas seega, et Abilify kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What is Abilify and what is it used for?
Estonian: Mis on Abilify ja milleks seda kasutatakse?
English: Why is Abilify approved?
Estonian: Miks Abilify heaks kiideti?
English: It can also be used for up to 12 weeks to treat manic episodes in adolescents from the age of 13 years.
Estonian: Abilifyt tohib samuti kasutada kuni 12 nädala jooksul maaniaepisoodide raviks vähemalt 13-aastastel noorukitel.
English: In adults, the most common side effects when taking Abilify by mouth (occurring in up to 10 patients in 100) are restlessness, difficulty sleeping, anxiety, extrapyramidal disorder (uncontrolled twitching or jerking), akathisia (a constant urge to move), tremor (shaking), dizziness, sleepiness, headache, blurred vision, dyspepsia (heartburn), vomiting, nausea (feeling sick), constipation, salivary hypersecretion (increased production of saliva), tiredness and diabetes.
Estonian: Abilify kõige sagedamad kõrvalnähud suukaudsel kasutamisel täiskasvanutel (esinenud kuni 10 patsiendil 100st) on rahutus, unetus, ärevus, ekstrapüramidaalne häire (tahtele allumatud tõmblused), akatiisia (motoorne rahutus), värin, peapööritus, unisus, uimasus, peavalu, nägemise ähmastumine, düspepsia (kõrvetised), oksendamine, iiveldus, kõhukinnisus, süljevoolus, väsimus ja diabeet.
English: This is a summary of the European public assessment report (EPAR) for Abilify.
Estonian: See on ravimi Abilify Euroopa avaliku hindamisaruande kokkuvõte.
English: By attaching to these receptors, it is thought that aripiprazole helps normalise the activity of the brain, reducing psychotic or manic symptoms and preventing them from returning.
Estonian: Nende retseptoritega seondudes aitab aripiprasool ajutegevust normaliseerida, vähendades psühhoosi- või maaniasümptomeid nign takistades nende taastumist.
English: The side effects are similar in adolescents, but sleepiness, extrapyramidal disorder, akathisia and tiredness are very common in this group (in more than 1 in 10 adolescents).
Estonian: Noorukite kõrvalnähud olid sarnased, kuid unisus, ekstrapüramidaalne häire, akatiisia ja väsimus on selles patsiendirühmas väga tavalised (enam kui 1 noorukil 10st).
English: The most common side effects with the injection (occurring in up to 10 patients in 100) are sleepiness, dizziness and nausea.
Estonian: Süste kõige sagedamad kõrvalnähud (esinenud kuni 10 patsiendil 100st) on unisus, peapööritus ja iiveldus.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Abilify have been included in the summary of product characteristics and the package leaflet.
Estonian: Abilify ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is not intended to provide practical advice on how to use Abilify.
Estonian: Hindamisaruandes ei anta Abilify kasutamise praktilisi nõuandeid.
English: Studies showed that Abilify is effective at treating symptoms of schizophrenia using standard rating scales (such as the Positive and Negative Syndrome Scale, PANSS).
Estonian: Uuringute järgi on Abilify efektiivne skisofreenia sümptomite ravis, mõõdetuna standardse skaala abil (näiteks positiivsete ja negatiivsete sümptomite skaala, PANSS).
English: For practical information about using Abilify, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Abilify kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Studies comparing Abilify to placebo or other medicines (such as haloperidol and lithium) show that Abilify is effective at reducing symptoms of schizophrenia and at treating and preventing high moods in patients with bipolar I disorder.
Estonian: Uuringud, milles võrreldi Abilifyt platseebo või muude ravimitega (näiteks haloperidooli ja liitiumiga) tõendavad, et Abilify on efektiivne skisofreenia sümptomite vähendamisel ning I tüüpi bipolaarse häirega patsientide maaniaepisoodide ravis ja ennetamisel.
English: Abilify has also been studied in 302 adolescents aged between 13 and 17, with results showing Abilify to be more effective than placebo.
Estonian: Abilifyt uuriti ka 302 noorukil vanuses 13-17 aastat; uuringu järgi oli Abilify efektiivsem kui platseebo.
English: Bipolar I disorder
Estonian: I tüüpi bipolaarne häire
English: The exact way it works is not known but it attaches in the brain to receptors for two substances (neurotransmitters) called dopamine and serotonin (5HT), which are believed to play a role in schizophrenia and bipolar disorder.
Estonian: Aripiprasooli täpne toimemehhanism ei ole teada, kuid see seondub ajus skisofreenia ja bipolaarse meeleoluhäire tekkes osalevate neurotransmitterite (virgatsainete) dopamiini ja serotoniini (5-hüdroksütrüptamiini) retseptoritega.
English: Abilify aripiprazole
Estonian: Abilify aripiprasool
English: For more information about treatment with Abilify, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Abilifyga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What benefits of Abilify have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Abilify kasulikkus?
English: What is the risk associated with Abilify?
Estonian: Mis riskid Abilifyga kaasnevad?
English: Other studies showed that Abilify was more effective than placebo at preventing manic episodes in previously treated adults for up to 74 weeks, and when it was used as an add-on to existing treatment.
Estonian: Muudes uuringutes oli olemasolevale ravile lisamisel Abilify platseebost efektiivsem maaniaepisoodide taastekke ennetamisel täiskasvanutel, keda oli varem ravitud kuni 74 nädala jooksul.
English: Abilify is an antipsychotic medicine for patients with schizophrenia and bipolar I disorder.
Estonian: Abilify on antipsühhootikum, mida kasutatakse skisofreenia ja I tüüpi bipolaarse meeleoluhäire ravis.
English: In 4 out of 5 studies in 1,900 adults, Abilify was more effective than placebo at reducing manic symptoms, with two of these studies showing that Abilify has a similar effect to haloperidol and to lithium.
Estonian: 4 uuringus 5st (1900 täiskasvanut) oli Abilify maaniasümptomite vähendamisel efektiivsem kui platseebo; neist uuringuist kahes sarnanes Abilify toime haloperidooli ja liitiumi toimega.
English: In addition, the injection has been shown to be effective at quickly controlling agitation or disturbing behaviour in patients with schizophrenia or bipolar I disorder.
Estonian: Lisaks on tõendatud, et süstitav ravimvorm on efektiivne rahutuse või häiritud käitumise kiireks ohjamiseks skisofreeniaga või I tüüpi bipolaarse häirega patsientidel.
English: The injection is used only for quickly controlling agitation or disturbed behaviour in patients with schizophrenia or bipolar I disorder.
Estonian: Süstet kasutatakse ainult rahutuse või häiritud käitumise kiireks ohjamiseks skisofreeniaga või I tüüpi bipolaarse häirega patsientidel.
English: In bipolar I disorder, Abilify is used in adults to treat manic episodes (periods of abnormally high mood) and to prevent new ones in those who have responded to the medicine in the past.
Estonian: I tüüpi bipolaarse häire korral kasutatakse Abilifyt maaniaepisoodide (meeleolu äärmuslik tõus) raviks ja uute maaniaepisoodide ennetamiseks täiskasvanutel, kellel on varem tekkinud sellele ravimile ravivastus.
English: For information on the dose and dose adjustments, see the package leaflet.
Estonian: Annuse ja annuse kohandamise teave on pakendi infolehel.
English: Studies in bipolar I disorder showed that Abilify is effective at treating manic episodes using standard measurements such as the Young-Mania Rating Scale (YMRS) scale.
Estonian: I tüüpi bipolaarse meeleoluhäirega patsientide uuringutes oli Abilify efektiivne maaniaepisoodide ravis, mõõdetuna standardse skaala abil (näiteks Youngi maania hindamise skaala, YMRS).
English: The active substance in Abilify is aripiprazole.
Estonian: Abilify toimeaine on aripiprasool.
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Abilify kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: In studies of 1,203 adults, Abilify was more effective than placebo (a dummy treatment) at reducing symptoms.
Estonian: Ühes uuringus (1203 täiskasvanut) vähendas Abilify sümptomeid efektiivsemalt kui platseebo (näiv ravim).
English: Abilify can only be obtained with a prescription.
Estonian: Abilify on retseptiravim.
English: A study in 544 patients treated by injection for agitation and disturbed behaviour showed that improvement with Abilify over 24 hours was greater than with placebo and similar to that with haloperidol.
Estonian: Rahutuse või häiritud käitumise süstega ravimise uuringus (544 patsienti) paranes patsientide seisund Ability kasutamisel 24 tunni jooksul rohkem kui platseeboga ja tulemus sarnanes seisundi paranemisega haloperidooli kasutamisel.
English: In schizophrenia, a mental illness with symptoms such as delusions, disorganised speech, and hallucinations (hearing or seeing things that are not there), Abilify is used to treat patients from the age of 15 years.
Estonian: Skisofreenia on vaimuhaigus, millel on mitmesugused sümptomid, näiteks luulud, kõnehäired ja hallutsinatsioonid (ebareaalsete asjade kuulmine või nägemine).
English: In another adult study, Abilify was as effective as haloperidol, another antipsychotic medicine, in preventing symptoms from returning over 1 year.
Estonian: Teises täiskasvanute uuringus takistas Abilify sümptomite taasteket 1 aasta jooksul sama efektiivselt kui haloperidool (samuti antipsühhootikum).
English: Finally, a study in 291 patients treated by injection for agitation and disturbed behaviour showed that improvement with Abilify was greater after 2 hours than with placebo and similar to that with lorazepam (another medicine for treating agitation).
Estonian: Rahutuse või häiritud käitumise süstega ravimise uuringus (291 patsienti) paranes patsientide seisund Ability kasutamisel 2 tunni jooksul rohkem kui platseeboga ja tulemus sarnanes seisundi paranemisega loratseptaami kasutamisel (samuti rahutuse ravim).
English: A study in 296 children and adolescents showed that Abilify was more effective than placebo at reducing the manic symptoms in patients aged 13 years and older.
Estonian: Vähemalt 13-aastaste patsientide uuringus (296 last ja noorukit) oli Abilify maaniasümptomite vähendamisel efektiivsem kui platseebo.
English: Abilify is available as tablets and a liquid to be taken by mouth.
Estonian: Abilifyt turustatakse tablettide ja suukaudse vedelikuna.
English: How is Abilify used?
Estonian: Kuidas Abilifyt kasutatakse?
English: Helixate NexGen is intended for either short-term or long-term use.
Estonian: Helixate NexGen on ette nähtud lühiajaliseks või pikaajaliseks kasutamiseks.
English: Stopping bleeding was assessed as ‘excellent' in all 15 patients.
Estonian: Verejooksu peatamine hinnati suurepäraseks kõigil 15 patsiendil.
English: The full EPAR for Helixate NexGen can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Helixate NexGen kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Skin- associated hypersensitivity reactions (itching, hives and rash) may occur commonly (in between 1 and 10 patients in 100) but a severe allergic reaction is rare (between 1 and 10 in 10,000 patients).
Estonian: Nahaga seotud ülitundlikkusreaktsioone (sügelus, nõgeslööve ja lööve) võib esineda sageli (1-10 patsiendil 100st), kuid raskeid allergiareaktsioone esineb harva (1-10 patsiendil 10 000st).
English: The main measure of effectiveness was the doctor's assessment of how well bleeding was stopped.
Estonian: Efektiivsuse põhinäitaja oli arsti hinnang, kui hästi suudeti verejooks peatada.
English: Patients or their carers may be able to administer Helixate NexGen themselves at home once they have been trained appropriately.
Estonian: Patsiendid või nende hooldajad tohivad ravimit Helixate NexGen kodus ise manustada, kui on saanud asjakohase väljaõppe.
English: What measures are being taken to ensure the safe and effective use of Helixate NexGen?
Estonian: Mis meetmed võetakse, et tagada ravimi Helixate NexGen ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the EU for Helixate NexGen on 4 August 2000.
Estonian: Euroopa Komisjon andis ravimi Helixate NexGen müügiloa, mis kehtib kogu Euroopa Liidus, 4. augustil
English: The Agency decided that Helixate NexGen's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Amet otsustas, et ravimi Helixate NexGen kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The main measure of effectiveness in the studies was the number of treatments required to stop each new bleed.
Estonian: Efektiivsuse põhinäitaja oli iga uue verejooksu peatamiseks vajalike manustuskordade arv.
English: The dose and duration of treatment depend on whether Helixate NexGen is used to treat or prevent bleeding or during surgery, as well as on the patient's factor VIII levels, the seriousness of the haemophilia, the extent and location of the bleeding and the patient's condition and bodyweight.
Estonian: Annus ja ravi kestus sõltuvad sellest, kas ravimit Helixate NexGen kasutatakse operatsiooniaegse verejooksu raviks või ennetamiseks, patsiendi VIII hüübimisfaktori sisaldusest, hemofiilia raskusastmest, verejooksu ulatusest ja asukohast ning patsiendi seisundist ja kehamassist.
English: EPAR summary for the public octocog alfa
Estonian: Kokkuvõte üldsusele alfaoktokog
English: This is a summary of the European public assessment report (EPAR) for Helixate NexGen.
Estonian: See on ravimi Helixate NexGen Euroopa avaliku hindamisaruande kokkuvõte.
English: Because of this, Helixate NexGen has been compared with Helixate to show that the two medicines are equivalent.
Estonian: Seetõttu võrreldi ravimit Helixate NexGen ravimiga Helixate, et tõendada nende kahe ravimi ekvivalentsust.
English: What is Helixate NexGen and what is it used for?
Estonian: Mis on Helixate NexGen ja milleks seda kasutatakse?
English: Octocog alfa is made by a method known as ‘recombinant DNA technology': it is made by cells into which a gene (DNA) has been introduced that makes them able to produce it.
Estonian: Alfaoktokogi valmistatakse rekombinant-DNA-tehnika abil: seda toodavad rakud, millesse on lisatud alfaoktokogi teket võimaldav geen (DNA).
English: Other information about Helixate NexGen
Estonian: Muu teave ravimi Helixate NexGen kohta
English: Helixate NexGen given as an injection into a vein has been studied in 66 patients who had previously been treated with recombinant human coagulation factor VIII and 61 children who had not.
Estonian: Veenisüstega manustatavat ravimit Helixate NexGen uuriti 66 patsiendil, keda oli varem ravitud rekombinantse VIII inimhüübimisfaktoriga, ning 61 lapsel, keda ei olnud varem ravitud.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Helixate NexGen have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Helixate NexGen ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The dose may need to be adjusted if Helixate NexGen is to be given continuously as an infusion into a vein.
Estonian: Annust võib olla vaja kohandada, kui ravimit Helixate NexGen manustatakse veeni pidevinfusioonina.
English: In the previously treated patients, overall, 95% of bleeds responded to one or two injections of Helixate NexGen into a vein.
Estonian: Varem ravitud patsientide verejooksudest reageeris kokku 95% ravimi Helixate NexGen ühele või kahele veenisüstele.
English: The Agency concluded that Helixate NexGen has been shown to be effective at treating and preventing bleeding in patients with haemophilia A and has an acceptable safety profile.
Estonian: Amet järeldas, et Helixate NexGen on osutunud A-hemofiiliaga patsientidel verejooksude ravimisel ja ennetamisel efektiivseks ning sel on vastuvõetav ohutusprofiil.
English: It is not intended to provide practical advice on how to use Helixate NexGen.
Estonian: Hindamisaruandes ei anta ravimi Helixate NexGen kasutamise praktilisi nõuandeid.
English: In the previously untreated patients, about 90% of bleeding episodes responded to treatment with one or two injections into a vein.
Estonian: Varem ravimata patsientide verejooksudest reageeris ligikaudu 90% ühele või kahele veenisüstele.
English: Helixate NexGen is similar to another medicine that was previously authorised in the EU called Helixate, but it is prepared differently so that there are no human-derived proteins in the medicine.
Estonian: Helixate NexGen sarnaneb Euroopa Liidus heaks kiidetud ravimile Helixate, kuid seda toodetakse teistmoodi, nii et ravimis ei leidu inimpäritoluga valke.
English: For practical information about using Helixate NexGen, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Helixate NexGen kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.